id: NEW:covid_19_critical_illness_to_acute_kidney_injury_hospitalization
name: COVID-19 Critical Illness (ICU Admission) â†’ Acute Kidney Injury Hospitalization
from_node:
  node_id: NEW:covid_19_critical_illness
  node_name: COVID-19 Critical Illness (ICU Admission)
to_node:
  node_id: acute_kidney_injury_hospitalization
  node_name: Acute Kidney Injury Hospitalization
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: SARS-CoV-2 binds to angiotensin converting enzyme 2 (ACE2) receptors, which
  are highly expressed in kidney proximal tubular cells, enabling viral entry and
  direct renal injury'
- 'Step 2: Critical illness in COVID-19 ICU patients triggers systemic inflammatory
  responses, cytokine storms, and hemodynamic instability leading to renal hypoperfusion'
- 'Step 3: Shock and vasopressor use in critically ill patients further compromises
  renal blood flow and tubular function'
- 'Step 4: Combined direct viral injury, systemic inflammation, and hemodynamic compromise
  result in acute kidney injury requiring hospitalization and potentially renal replacement
  therapy'
evidence:
  quality_rating: A
  n_studies: 74
  primary_citation: 'A. Cau et al. 2021. Acute Kidney Injury and Renal Replacement
    Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and
    Meta-Analysis. Canadian Journal of Kidney Health and Disease.'
  supporting_citations: []
description: Critically ill COVID-19 patients admitted to the ICU have a 51% pooled
  rate of developing acute kidney injury. The mechanism involves direct viral injury
  through ACE2 receptor binding in kidney tissue, systemic inflammatory responses,
  and hemodynamic instability including shock requiring vasopressors. Approximately
  20% of critically ill COVID-19 patients require renal replacement therapy.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 0.51
    type: pooled_proportion
    ci_lower: 0.44
    ci_upper: 0.57
  p_value: null
  sample_size: 23655
moderators:
- name: shock_or_vasopressor_use
  direction: strengthens
  strength: strong
  description: After adjusting for shock or vasopressor use, AKI rates between virus
    groups were not significantly different, suggesting shock/vasopressor use is a
    key mediator of the AKI risk
- name: ACE2_receptor_binding
  direction: weakens
  strength: moderate
  description: COVID-19 and other ACE2-associated viruses showed lower RRT rates (20%)
    compared to non-ACE2-associated viruses (49%), possibly due to lower frequencies
    of shock in ACE2-associated infections
